Stock Events

Shield Therapeutics 

€0.06
22
+€0+0% Friday 06:03

Statistics

Day High
0.06
Day Low
0.06
52W High
-
52W Low
-
Volume
0
Avg. Volume
-
Mkt Cap
46.46M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

4SepExpected
Q1 2024
Q2 2024
-0.02
0.32
0.65
0.98
Expected EPS
N/A
Actual EPS
-0.018048

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1JS.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap179.38B
Amgen develops treatments in areas similar to Shield Therapeutics, including anemia which directly competes with Shield's Feraccru/Iron product.
Abbvie
ABBV
Mkt Cap346.75B
AbbVie competes in the pharmaceutical space with products that could serve as alternatives to treatments offered by Shield Therapeutics, especially in gastrointestinal and chronic conditions.
Astrazeneca
AZN
Mkt Cap271.67B
AstraZeneca operates in similar therapeutic areas as Shield, including treatments for anemia and other conditions that Shield's products address.
Johnson & Johnson
JNJ
Mkt Cap399.26B
Johnson & Johnson, through its pharmaceutical division Janssen, offers a wide range of products that compete across the board with Shield's portfolio, including anemia and chronic disease treatments.
GSK
GSK
Mkt Cap89.55B
GlaxoSmithKline has a broad portfolio that includes treatments for conditions like anemia, competing with Shield's main product offerings.
Pfizer
PFE
Mkt Cap164.39B
Pfizer has a diverse drug portfolio that includes treatments in areas competing with Shield Therapeutics, particularly in chronic diseases and conditions treated by Shield's products.
Novartis
NVS
Mkt Cap244.75B
Novartis offers a wide range of pharmaceutical products, including those for anemia and chronic conditions, directly competing with Shield Therapeutics' market.
Bristol-Myers Squibb
BMY
Mkt Cap101.27B
Bristol Myers Squibb competes in the global pharmaceutical market with a focus on serious diseases, including areas that overlap with Shield Therapeutics' focus areas.
Merck
MRK
Mkt Cap300.25B
Merck operates in various therapeutic areas, including those that compete with Shield Therapeutics, offering alternative treatments for conditions like anemia.
Sanofi
SNY
Mkt Cap141.43B
Sanofi produces a range of pharmaceutical products that compete with Shield Therapeutics, especially in the chronic disease treatment space.

About

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.
Show more...
CEO
Mr. Anders Lundstrom
Employees
73
Country
GB
ISIN
GB00BYV81293
WKN
000A2AE98

Listings